1. Japan Stocks

  2. •

    Commercial services

  3. •

    Miscellaneous commercial services
Tsubota Laboratory Incorporated

Tsubota Laboratory Incorporated

TTSE:4890
256.00
JPY
-4.00
(-1.54%)
7.58BMarket Cap
Nov 11Next Earn
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
17.57
30.59
28.32
38.78
26.33
53.03
7.77
- -
Basic EPS, GAAP
0.12
8.97
6.77
3.66
-25.07
8.04
-29.58
- -
Free Cash Flow per Basic Share
10.29
-0.38
25.75
-0.82
-12.25
-13.15
-22.78
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
13.15
23.52
29.62
77.07
53.45
61.91
33.49
- -
Tangible Book Value per Share
13.02
23
29.02
76.61
53.11
61.64
33.3
- -
Basic Weighted Avg Shares
25
22
23
25
26
26
26
26
Sales/Revenue/Turnover
442
688
641
955
674
1,357
200
- -
Operating Margin (%)
3.32
36.4
21.25
17.5
-96.44
17.35
-393.87
- -
Depreciation Expense
3
14
38
39
36
29
21
- -
Net Income, GAAP
3
202
153
90
-641
206
-762
- -
Effective Tax Rate (%)
18.24
21.2
24.23
37.47
- -
26.79
- -
- -
Profit Margin (%)
0.68
29.32
23.92
9.45
-95.22
15.16
-380.87
- -
Working Capital
355
740
841
1,961
1,386
1,599
873
- -
LT Debt
50
224
199
115
90
69
47
- -
Total Equity
330
591
744
1,950
1,367
1,587
864
- -
Return on Invested Capital (%)
- -
29.94
10.8
6.69
- -
10.58
- -
- -
Return on Capital (%)
- -
33.09
17.11
5.93
- -
13.07
- -
- -
Return on Common Equity (%)
- -
43.76
22.96
6.69
-38.66
13.93
-62.16
- -

Capital Structure

JPY

•

in mil. unless spec.
Sep'26
Mar'26
Jun'27
ST Debt
22
22
- -
LT Borrowings
58
47
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
26
26
26
Market Capitalization
9,183
7,584
5,907

Working Capital

JPY

•

in mil. unless spec.
Sep'26
Mar'26
Jun'27
Total Current Assets
1,840
1,281
- -
Cash, Cash Equivalents & STI
1,388
970
- -
Accounts Receivable, Net
56
14
- -
Inventories
286
189
- -
Total Current Liabilities
539
408
- -
Payables & Accruals
- -
- -
- -
ST Debt
22
22
- -
Deferred Revenue
- -
- -
- -

Growth Rates

JPY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
25.71%
-45.58%
Free Cash Flow
- -
-1,086.11%
74.34%
Net Income, GAAP
- -
-295.72%
-470.23%
Sales/Revenue/Turnover
- -
5.79%
-85.26%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
1,357
2026
- -
- -
- -
- -
200
2027
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
8.04
2026
- -
- -
- -
- -
-29.58
2027
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Kazuo Tsubota
Full Time Employees
22
Sector
Commercial services
Industry
Miscellaneous commercial services
Address
CRIK Shinanomachi E7, Bldg. 2 Tokyo TY Japan 160-8582
IPO Date
Jun 23, 2022
Website
tsubota-lab.com
Similar Companies
PayPal Holdings, Inc. (NASDAQ:PYPL)
Shopify Inc. (NASDAQ:SHOP)
Greenland Mines Ltd (NASDAQ:GRML)
Block, Inc. (NYSE:XYZ)
Netcapital Inc. (NASDAQ:NCPL)
Shopify, Inc. Class A (TSX:SHOP)
Business
Tsubota Laboratory Incorporated engages in the research, development, and commercialization of pharmaceuticals, medical devices, and health products primarily targeting myopia, dry eye, presbyopia, depression, dementia, sleep improvement, and concentration enhancement; core offerings include innovative eyeglasses such as myopia prevention models utilizing violet light exposure (360-400 nm wavelength), meibomian gland dysfunction treatments like TLM-001, keratoconus therapies, and pipelines for ophthalmic and neurological conditions delivered via a B2B model through joint research, licensing agreements, milestone payments, and royalties. The company operates in the medical equipment manufacturing and biotechnology sectors, serving partner pharmaceutical firms, clinics, and global markets with a focus on Japan, Asia, Europe, China, and the United States. Founded in 2012 and headquartered at CRIK Shinanomachi E7 Building, 9th Floor, Keio University Shinanomachi Campus, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan, Tsubota Laboratory employs approximately 17 people under CEO Kazuo Tsubota. Recent developments include a licensing agreement with an overseas pharmaceutical company on non-clinical and partial clinical trial data for key pipelines, achieving significant profit growth and return to profitability in the third quarter of fiscal 2024; unveiling of the new AEONIA model cosmetics device on November 5, 2025, through partnership with Delavie Sciences for clinic sales channels; and obtaining a manufacturing and marketing license for cosmetics to expand into Japan's cosmetics business while maximizing global pipeline value via strategic partnerships.